Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eclipse Eying Profitability As Medicare TMR Reimbursement Comes On Line

This article was originally published in The Gray Sheet

Executive Summary

Eclipse Surgical Technologies is conducting three training programs per month at five U.S. centers in anticipation of Medicare reimbursement coverage for surgical transmyocardial revascularization (TMR) procedures, scheduled to take effect July 1, President and CEO Allen Hill reported June 7 at the Paine Webber 10th Annual Growth & Technology Conference in New York City.

You may also be interested in...



BlueCross BlueShield Assessment Okays Combined TMR/CABG Procedure

Transmyocardial revascularization (TMR) performed in conjunction with coronary artery bypass graft surgery on certain patients meet BlueCross BlueShield Association Technology Evaluation Center assessment criteria, according to an assessment summary.

BlueCross BlueShield Assessment Okays Combined TMR/CABG Procedure

Transmyocardial revascularization (TMR) performed in conjunction with coronary artery bypass graft surgery on certain patients meet BlueCross BlueShield Association Technology Evaluation Center assessment criteria, according to an assessment summary.

Laser Myocardial Therapies Under The Beam In Light Of J&J DIRECT Results

Results of a Johnson & Johnson-sponsored trial showing that direct myocardial revascularization (DMR) technology has a placebo-comparable effect should prompt FDA to take a closer look at laser therapies for advanced heart disease patients, trial investigators suggest.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel